tenofovir has been researched along with lopinavir in 136 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.47) | 18.2507 |
| 2000's | 39 (28.68) | 29.6817 |
| 2010's | 82 (60.29) | 24.3611 |
| 2020's | 13 (9.56) | 2.80 |
| Authors | Studies |
|---|---|
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Chen, YC; Dumond, JB; Fiscus, SA; Horton, AL; Kashuba, AD; Patterson, KB; Rezk, NL; Tappouni, HL; Tien, HC; Vourvahis, M; Yeh, RF | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
| Schouten, J | 1 |
| Gallant, JE | 1 |
| Brun, S; Di Mascio, M; Ho, DD; Hogan, C; Hurley, A; Louie, M; Markowitz, M; Perelson, AS; Rooney, J; Ruiz, N; Simon, V; Sun, E | 1 |
| Abad, S; Blanche, P; Chauvelot-Moachon, L; Daniel, N; Kélaïdi, C; Nazal, EM; Rollot, F; Saba, M | 1 |
| Carter, M | 1 |
| Chaix, ML; Delaugerre, C; Peytavin, G; Roudiere, L; Rouzioux, C; Viard, JP | 1 |
| Bannister, A; Day, SL; Fisher, M; Hankins, M; Leake Date, HA | 1 |
| Dalmau, D; Ferrer, E; Gatell, JM; Iniguez, D; Knobel, H; Leon, A; Niubo, J; Podzamczer, D; Polo, C; Ruiz, I | 1 |
| Mallal, S; Nolan, D; Reiss, P | 1 |
| Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; Rightmire, A; Rodriguez, C; Sankoh, S; Wilber, R | 1 |
| Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; McLaren, C; Odeshoo, L; Rightmire, A; Rodriguez, C; Wirtz, V | 1 |
| Bonjoch, A; Bravo, I; Clotet, B; Heilek-Sneider, GM; Martinez-Picado, J; Moltó, J; Negredo, E; Ruiz, L; Valle, M | 1 |
| Hussain, S; Khayat, A; Rathore, MH; Tolaymat, A | 1 |
| Gatanaga, H; Genka, I; Honda, M; Kikuchi, Y; Kimura, S; Oka, S; Tachikawa, N; Tanuma, J; Teruya, K; Ueda, A; Yazaki, H | 1 |
| Alvarez, ML; Cihlar, T; Cordobilla, B; Domingo, JC; Domingo, P; Giralt, M; Guallar, J; López-Dupla, M; Sánchez de la Rosa, R; Saumoy, M; Torres, F; Vidal, F; Villarroya, F | 1 |
| Baker, RK; Brooks, JT; Buchacz, K; Chmiel, JS; Moorman, A; Wood, KC; Young, B | 1 |
| Bainbridge, A; Jäger, HR; Miller, RF; Usiskin, SI | 1 |
| Amoroso, A; Chan-Tack, KM; Kopack, AM; Polk, C | 1 |
| Calvez, V; Chaix, ML; Delaugerre, C; Girard, PM; Katlama, C; Marcelin, AG; Morand-Joubert, L; Soulié, C | 1 |
| Anderson, PL; Aquilante, CL; Bushman, LR; Carten, ML; Delahunty, T; Fletcher, CV; King, TM; Kiser, JJ; Wolfe, P | 1 |
| Cascone, A; Colella, G; Di Martino, F; Filippini, A; Filippini, P; Lanza, A; Martini, S; Masiello, A; Pisapia, R | 1 |
| Acosta, EP; Binongo, JN; Chuck, SK; Lennox, JL; Ofotokun, I; Palau, M | 1 |
| Corona, G; Innocenti, F; Sandron, S; Sartor, I; Tirelli, U; Toffoli, G; Vaccher, E | 1 |
| Bridges, AS; Cohen, MS; Corbett, AH; Dumond, JB; Jung, BH; Kashuba, AD; Patterson, KB; Rezk, NL; Stewart, PW; Yeh, RF | 1 |
| Geretti, AM | 1 |
| Bulgin-Coleman, D; Fath, M; Fontaine, L; Kantor, C; Mieras, J; Pierone, G; Shearer, J | 1 |
| Ray, AS; Rhodes, GR; Wright, MR | 1 |
| Cotter, BR; Currier, JS; Dubé, MP; Fichtenbaum, CJ; Gerschenson, M; Komarow, L; Mitchell, CK; Murphy, RL; Parker, RA; Squires, K; Stein, JH; Torriani, FJ | 1 |
| Moreno, V; Valencia, ME | 1 |
| Ayen, R; Clotet, B; Grassi, J; Levi, M; Negredo, E; Pruvost, A; Puig, J; Théodoro, F | 1 |
| Belsey, E; Berzins, B; Chen, D; Choi, J; da Silva, B; Gerschenson, M; Kim, C; Libutti, DE; McComsey, GA; Murphy, RL; Shore, J; Taiwo, B; Weinstein, J | 1 |
| Bellos, N; Fine, D; Kumar, PN; Lackey, P; Patel, P; Shaefer, MS; Sloan, L; Smith, KY; Sutherland-Phillips, DH; Vavro, C; Wannamaker, P; Yau, L | 1 |
| Andrade, A; Eshleman, SH; Flanigan, T; Flexner, C; Gross, R; Hogg, E; Lalama, C; Mildvan, D; Reisler, R; Rosenkranz, S; Salomon, N; Santana, J; Tierney, C; Wiggins, I | 1 |
| Chetchotisakd, P | 1 |
| Bangsberg, DR | 1 |
| Absalon, J; Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Lataillade, M; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Wirtz, V; Yang, R | 1 |
| Battegay, M; Bernasconi, E; Cavassini, M; Elzi, L; Furrer, H; Hirschel, B; Ledergerber, B; Marzolini, C; Vernazza, P; Weber, R | 1 |
| Altice, FL; Springer, SA | 1 |
| Absalon, J; Malan, N; Mancini, M; McGrath, D; Su, J; Wirtz, V; Yang, R | 1 |
| Bernstein, B; Cohen, D; da Silva, B; Fredrick, L; González-García, J; Johnson, M; Naylor, C; Sloan, L | 1 |
| Benabdelmoumen, G; Bouvet, E; Christian, B; Muller, P; Peyrouse, E; Prazuck, T; Quertainmont, Y; Rabaud, C; Tosini, W | 1 |
| Aba, YT; Aoussi, EF; Bissagnene, E; Eholié, SP; Ehui, E; Kadio, A; Kakou, AR; Kassi, A; Ondounda, M; Ouattara, I; Tanon, A | 1 |
| Alston-Smith, B; Asmelash, A; Atwine, D; Chipato, T; Conradie, F; Currier, JS; Eshleman, S; Hakim, J; Hogg, E; Hosseinipour, MC; Hughes, MD; Kanyama, C; Lockman, S; McIntyre, J; Mellors, JW; Mngqibisa, R; Mohapi, L; Purcelle-Smith, E; Rahim, S; Rooney, J; Salata, RA; Sawe, F; Schooley, RT; Shaffer, D; Siika, A; Stringer, E; Walawander, A; Wools-Kaloustian, K; Zheng, Y | 1 |
| Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF | 1 |
| Bentley, TG; Broder, MS; Chang, EY; Juday, T; Uy, J | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Lavreys, L; Picchio, G; Van de Casteele, T | 1 |
| Farajallah, A; McGrath, D; Sheppard, L; Uy, J; Wirtz, V; Yang, R | 1 |
| Gatanaga, H; Kikuchi, Y; Nagata, N; Nishijima, T; Oka, S; Teruya, K; Tsukada, K; Watanabe, K | 1 |
| Abraham, B; Bélec, L; Charpentier, C; Dandy, M; De Dieu Longo, J; Grésenguet, G; Matta, M; Mbelesso, P; Moussa, S; Péré, H | 1 |
| Furrer, H; Rauch, A; Wandeler, G | 1 |
| Caro-Vega, Y; Crabtree-Ramírez, B; López-Martínez, A; O'Brien, NM; Sierra-Madero, J | 1 |
| Bertz, R; Child, M; Eley, T; Farajallah, A; Krystal, M; Liao, S; McGrath, D; Molina, JM; Persson, A; Sevinsky, H; Xu, X; Zhang, J; Zhu, L | 1 |
| Chipato, T; Cole, SR; Currier, JS; D'Amico, R; Eron, JJ; Hosseinipour, M; Hughes, MD; Lockman, S; McCarthy, JS; Meshnick, SR; Poole, C; Porter, KA; Salata, R; Sawe, FK; Shaffer, D; Siika, A; Skinner-Adams, TS; Stringer, E; Zheng, Y | 1 |
| Camp, R; Connick, E; Daar, ES; Degruttola, V; Del Rio, C; Fiscus, SA; Hare, CB; Hogan, CM; Kallungal, B; Little, S; Macatangay, B; Markowitz, M; Morton, T; Sun, X; Tashima, KT | 1 |
| Conway, B; Tossonian, H | 1 |
| de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ | 1 |
| Bedimo, R; Drechsler, H; Maalouf, NM; Tebas, P; Zhang, S | 1 |
| Battegay, M; Bernasconi, E; Bucher, HC; Calmy, A; Cavassini, M; Furrer, H; Fux, CA; Schäfer, J; Vernazza, P; Weber, R; Young, J | 1 |
| Aga, E; Badal-Faesen, S; Bartlett, JA; Crump, JA; Hosseinipour, MC; Kallungal, BA; Katzenstein, DA; Klingman, KL; Kumarasamy, N; Norton, MR; Ribaudo, HJ; Stevens, WS; Supparatpinyo, K; Wallis, CL | 1 |
| Ciarlini, P; Folkerth, RD; Henrich, TJ; Johnson, JA; Klein, JP; Lyons, JL; Milner, DA; Phillips, RE; Schutten, M; Wood, BR | 1 |
| Borghi, V; Capetti, A; Cicconi, P; Di Biagio, A; Di Giambenedetto, S; Francisci, D; Giacometti, A; Giannarelli, D; Maggiolo, F; Monno, L; Penco, G; Prinapori, R; Sterrantino, G; Zoncada, A | 1 |
| Borderi, M; Calza, L; Colangeli, V; Di Bari, MA; Magistrelli, E; Manfredi, R; Salvadori, C; Trapani, F; Viale, P | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwattanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Klinbuayaem, V; Mahanontharit, A; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Valcour, V | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwatanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Kerr, SJ; Klinbuayaem, V; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Sungkanuparph, S | 1 |
| Cabie, A; Charpentier, C; Chene, G; Colin de Verdiere, N; Descamps, D; Fagard, C; Grondin, C; Joly, V; Raffi, F; Tabuteau, S; Yazdanpanah, Y; Yeni, P | 1 |
| Ambrosioni, J; Calmy, A; Daou, S; Merkler, D | 1 |
| Aguilar, A; De La Torre, J; Del Arco, A; García-Alegría, J; Olalla, J; Pombo, M; Prada, JL; Ruiz-Mateas, F; Urdiales, D | 1 |
| Abgrall, S; Antinori, A; Cavassini, M; Costagliola, D; Crane, HM; Gill, MJ; Gomez Sirvent, JL; Guest, JL; Ingle, SM; Manzardo, C; May, MT; Mercie, P; Mugavero, MJ; Phillips, A; Reekie, J; Reiss, P; Saag, MS; Samji, H; Stephan, C; Sterling, TR; Sterne, JA; Tate, J; Wasmuth, JC | 1 |
| Acosta, EP; Andrade, A; Campbell, T; Cillo, AR; Daar, ES; Feinberg, J; Flexner, C; Jacobson, JM; Kuritzkes, DR; Lederman, M; Lu, D; Mellors, JW; Rosenkranz, SL | 1 |
| Feucht, N; Hadeler, J; Lanzl, I; Loos, D; Schmid, RM; Schwerdtfeger, C; Spinner, CD | 1 |
| Endo, T; Fujii, T; Gatanaga, H; Horiba, M; Itoda, I; Koga, M; Komatsu, H; Mitsuya, H; Miyakawa, T; Naito, T; Nishijima, T; Oka, S; Shimbo, T; Takada, K; Tanabe, Y; Tei, M; Yamamoto, M | 1 |
| Currier, J; Hogg, E; Hosseinipour, M; Hughes, MD; Lockman, S; Mulenga, L; Mwafongo, A; Nkanaunena, K; Samaneka, W; Siika, A; Zheng, Y | 1 |
| Ananworanich, J; Bowonwattanuwong, C; Bunupuradah, T; Hirschel, B; Jirajariyavej, S; Klinbuayaem, V; Mahanontharit, A; Munsakul, W; Ruxrungtham, K; Sophonphan, J | 1 |
| DeGrosky, M; Farajallah, A; Hardy, H; McGrath, D; Moyle, GJ | 1 |
| Bao, Y; Currier, J; Hogg, E; Hughes, MD; Lockman, S; Moses, A; Sawe, F; Shaffer, D | 1 |
| Ho, RJ; Koehn, J | 1 |
| Domingo, JC; Domingo, P; Gallego-Escuredo, JM; Giralt, M; Gutierrez, Mdel M; Lamarca, K; Mateo, MG; Torres, F; Vidal, F; Villarroya, F; Villarroya, J | 1 |
| Asmelash, A; Currier, J; Hughes, MD; Kaloustian, KW; Lockman, S; Ogwu, A; Salata, R; Sawe, F; Shaffer, D; Zheng, Y | 1 |
| Clumeck, N; Delforge, M; Ilunga, J; Kabeya, K; Kadiebwe, D; Kapend, L; Kasamba, E; Matanda, S; Milolo, C; Mwamba, C; Necsoi, C; Vaira, D | 1 |
| Freeling, JP; Ho, RJ; Koehn, J; Shu, C; Sun, J | 2 |
| Arnedo, M; Domingo, P; Egaña-Gorroño, L; Escribà, T; Fontdevila, J; Gatell, JM; Loncà, M; Martínez, E; Negredo, E; Vidal, F | 1 |
| Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY | 1 |
| Fraenkel, L; Han, Y; Hsieh, E; Hu, YY; Insogna, K; Li, T; Xia, W; Xie, J; Yin, MT; Zhu, T | 1 |
| Brun-Vezinet, F; Costagliola, D; Mokhtari, S; Poizot-Martin, I; Potard, V; Pradier, C; Rey, D; Rozenbaum, W | 1 |
| Han, Y; Li, T; Li, Y; Qiu, Z; Song, X; Xie, J; Zhu, T | 1 |
| Ajose, O; Beanland, RL; Calmy, A; Doherty, M; Ford, N; Irvine, C; Mayer, KH; Rapparini, C; Shubber, Z; Vitoria, M | 1 |
| Klein, MB; Mucsi, I; Rollet-Kurhajec, KC; Young, J | 1 |
| Amin, J; Boyd, MA; Cooper, DA; Emery, S; Kelleher, AD; Losso, M; Madero, JS; Molina, JM; Moore, CL; Renjifo, B; Ruxrungtham, K; Teppler, H; Wolff, M; Wood, R | 1 |
| He, C; Huang, H; Liao, L; Liu, J; Ruan, Y; Shao, Y; Wang, J; Wang, Z; Xing, H; Yang, S; Yue, Y | 1 |
| Boissonnault, M; Charest, L; Galanakis, C; Huchet, E; Longpré, D; Machouf, N; Murphy, D; Thomas, R; Trottier, B; Vézina, S | 1 |
| Arastéh, K; Bergmann, F; Chaves, RL; Cooper, DA; Cordery, DV; Neto, JL; Robinson, P; Ruxrungtham, K; Scherer, J; Zajdenverg, R | 1 |
| Lytvyak, E; Mason, AL; Montano-Loza, AJ | 1 |
| Bowman, VQ; Daar, ES; Diamond, C; Dube, MP; Goicoechea, M; Haubrich, RH; Jain, S; Karris, MY; Kemper, C; Kerkar, S; Morris, S; Rieg, G; Sun, X | 1 |
| Carbone, A; Castagna, A; Galli, L; Gianotti, N; Lazzarin, A; Merli, M; Nozza, S; Poli, A; Ripa, M; Salpietro, S | 1 |
| Ammassari, A; Antinori, A; Bellagamba, R; Borghi, V; Colafigli, M; D'Ettorre, G; Di Giambenedetto, S; Fabbiani, M; Giannetti, A; Latini, A; Loiacono, L; Lorenzini, P; Sterrantino, G; Zaccarelli, M | 1 |
| Amin, J; Azwa, I; Belloso, WH; Boyd, MA; Chetchotisakd, P; Cooper, DA; Emery, S; Hoy, J; Kumarasamy, N; Lombaard, J; Mallon, PW; Mohapi, L; Molina, JM; Moore, CL; Phanuphak, P; Wood, R | 1 |
| Post, FA | 1 |
| Andrag, E; Conradie, M; Conradie, MM; Ferris, WF; van de Vyver, M | 1 |
| Incardona, F; Meini, G; Mloka, D; Mugusi, F; Mugusi, S; Neogi, U; Sönnerborg, A; Svärd, J; Zazzi, M | 1 |
| Agarwal, A; Alexander, PE; Chang, Y; Foroutan, F; Guyatt, GH; Hepworth, E; Lee, Y; Lesi, O; Mah Ming, J; Merglen, A; Mir, H; Mirza, R; Siemieniuk, RA; Zeraatkar, D; Zhang, Y | 1 |
| Shafer, RW | 1 |
| Avihingsanon, A; Burger, DM; Mitruk, S; Punyawudho, B; Rungtivasuwan, K; Ruxrungtham, K; Sukasem, C; Thammajaruk, N | 1 |
| Arnaiz, JA; Cruceta, A; García, F; Gatell, JM; González, E; González-Cordón, A; Inciarte, A; Laguno, M; Leal, L; León, A; Lucero, C; Mallolas, J; Martínez-Rebollar, M; Rojas, J; Torres, B | 1 |
| Collier, AC; Collins, C; Ho, RJY; Kinman, L; Koehn, J; Kraft, JC; McConnachie, LA; Shen, DD; Sun, J | 1 |
| Collier, AC; Ho, RJY; Kinman, LM; Koehn, J; Kraft, JC; Lane, S; Lee, W; McConnachie, LA | 1 |
| Gatanaga, H; Matsumoto, S; Mizushima, D; Nguyen, DT; Nguyen, DTH; Oka, S; Tanuma, J; Trung, NV; van Kinh, N | 1 |
| Barr, E; Chadwick, EG; Currier, JS; Hernandez-Diaz, S; Hoffman, RM; Huo, Y; Patel, K; Rough, K; Seage, GR; Shapiro, DE; Williams, PL | 1 |
| Collier, AC; Ho, RJY; Iwamoto, JF; Koehn, J; Kraft, JC; McConnachie, LA | 1 |
| Cattaneo, D; Perno, CF; Rizzardini, G | 1 |
| Tartaglia, A | 1 |
| Avihingsanon, A; Bukuru, A; Cardoso, SW; Collier, AC; Faesen, S; Godfrey, C; Grinsztejn, B; Gross, R; Hogg, E; Hughes, MD; Kanyama, C; Kumarasamy, N; Makanga, M; Mave, V; Mellors, JW; Mngqibisa, R; Mohapi, L; Montalban, E; Mugyenyi, P; Nerette Fontain, S; Ritz, J; Salata, R; Samaneka, W; Santos, BR; Schooley, RT; Secours, R; Sugandhavesa, P; Valencia, J; van Schalkwyk, M; Wallis, CL; Wangari Ndege, B; Wieclaw, L | 1 |
| Chi, BH; Fairlie, L; Farhad, M; Fenton, T; Fowler, MG; Moodley, D; Naik, S; Nakabiito, C; Stringer, JSA; Venkatesh, KK | 1 |
| Fischer, A; Gumede, SB; Lalla-Edward, ST; Venter, WDF | 1 |
| Aizire, J; Brooks, KM; Butler, K; Cababasay, M; Fenton, T; Flynn, PM; Fowler, MG; Kiser, JJ; Mirochnick, M; Siberry, GK | 1 |
| Duan, Y; Zhou, C; Zhu, HL | 1 |
| Rockstroh, JK; Waters, L | 1 |
| Adachi, E; Hoshina, T; Ikeuchi, K; Saito, M; Yotsuyanagi, H | 1 |
| Alonso-Castro, AJ; Alvarez-Alvarez, RM; Del Carmen Preciado-Puga, M; Del Rocio Ibarra-Reynoso, L; Lazo-de-la-Vega-Monroy, ML; Ruiz-Noa, Y; Ruiz-Padilla, AJ; Sánchez-Barajas, M | 1 |
| Ho, RJY; Lane, S; McConnachie, L; Yu, D; Yu, J | 1 |
| Aizire, J; Browning, R; Dadabhai, S; Fan, B; Fowler, MG; George, K; Mofenson, LM; Moodley, D; Mukwasi-Kahari, C; Nelson, B; Sebikari, D; Shepherd, J; Siberry, GK; Sommer, MJ; Stranix-Chibanda, L; Theron, G; Tierney, C; Vhembo, T; Violari, A; Zanga, A | 1 |
| Ho, RJY; Perazzolo, S; Shen, DD; Shireman, LM | 1 |
| Ho, RJY; Perazzolo, S; Shen, DD | 1 |
| Aidara, M; Alleyo, A; Diallo, K; Manga, NM; Wembulua, BS | 1 |
| Eleje, GU; Ikechebelu, JI; Nwagha, UI; Okafor, HU; Ugwu, AO; Ugwu, EO; Umeh, UA | 1 |
| Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L | 1 |
12 review(s) available for tenofovir and lopinavir
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Kidney Diseases; Lopinavir; Metabolic Syndrome; Nevirapine; Organophosphonates; Oxazines; Pyrimidinones; Risk Factors; Tenofovir | 2005 |
Resistance testing methodologies and mechanisms of resistance.
Topics: Adenine; Anti-HIV Agents; CCR5 Receptor Antagonists; Drug Resistance, Viral; HIV; Humans; Lopinavir; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Pyrimidinones; Tenofovir | 2007 |
The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Treatment Outcome | 2009 |
HIV-2 encephalitis: case report and literature review.
Topics: Adenine; Anti-HIV Agents; Brain; CD4 Lymphocyte Count; Deoxycytidine; Drug Combinations; Emtricitabine; Encephalitis, Viral; HIV-2; Humans; Lopinavir; Magnetic Resonance Imaging; Male; Middle Aged; Organophosphonates; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2012 |
Intracranial hypertension following highly active antiretroviral therapy interruption in an HIV-infected woman: case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Decompressive Craniectomy; Dideoxynucleosides; Female; Humans; Intracranial Hypertension; Lopinavir; Medication Adherence; Meningoencephalitis; Organophosphonates; Sulfonamides; Tenofovir; Treatment Outcome | 2013 |
48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Lopinavir; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Rilpivirine; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Humans; Lopinavir; Post-Exposure Prophylaxis; Ritonavir; Tenofovir; World Health Organization | 2015 |
Combination antiretroviral studies for patients with primary biliary cirrhosis.
Topics: Animals; Anti-Retroviral Agents; Betaretrovirus; Clinical Trials as Topic; Drug Therapy, Combination; Emtricitabine; Humans; Lamivudine; Liver Cirrhosis, Biliary; Lopinavir; Mammary Tumor Virus, Mouse; Mice; Tenofovir; Zidovudine | 2016 |
Managing chronic kidney disease in the older adults living with HIV.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Chronic Disease; Darunavir; Drug Substitution; HIV Infections; Humans; Kidney; Kidney Diseases; Lopinavir; Middle Aged; Tenofovir | 2017 |
Antiretroviral therapy for pregnant women living with HIV or hepatitis B: a systematic review and meta-analysis.
Topics: Adult; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Female; Hepatitis B; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Ritonavir; Tenofovir; Young Adult; Zidovudine | 2017 |
Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus.
Topics: Antiviral Agents; Coinfection; DNA, Viral; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B virus; HIV; HIV Infections; HIV Seropositivity; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnant Women; Ritonavir; Tenofovir; Zidovudine | 2023 |
51 trial(s) available for tenofovir and lopinavir
| Article | Year |
|---|---|
Determining the relative efficacy of highly active antiretroviral therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2003 |
Early virological failure with a combination of tenofovir, didanosine and efavirenz.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Organophosphonates; Oxazines; Pyrimidinones; RNA, Viral; Tenofovir; Time Factors; Treatment Failure; Viremia | 2005 |
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol; Drug Administration Schedule; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Viral Load | 2005 |
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Time Factors; Treatment Outcome | 2006 |
Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Lamivudine; Lopinavir; Organophosphonates; Oxazines; Patient Compliance; Peptide Fragments; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2006 |
Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.
Topics: Adenine; Adult; Atazanavir Sulfate; Cohort Studies; Female; HIV Infections; Humans; Kidney; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; Tenofovir | 2006 |
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
Topics: Adenine; Administration, Oral; Adult; Antiretroviral Therapy, Highly Active; Case-Control Studies; Drug Interactions; Female; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Lopinavir; Male; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transport Protein 1; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2008 |
Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.
Topics: Adenine; Adult; Area Under Curve; Capsules; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sex Factors; Tenofovir | 2007 |
An open-label pilot study to determine the efficacy of lopinavir/ritonavir and tenofovir DF in the treatment of HIV-infected patients experiencing first virologic failure on a non-nucleoside-based regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lopinavir; Middle Aged; Organophosphonates; Pilot Projects; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2008 |
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Brachial Artery; CD4 Lymphocyte Count; Cyclopropanes; Endothelium, Vascular; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir; Time Factors; Zidovudine | 2008 |
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Topics: Adenine; Adult; Anti-HIV Agents; Area Under Curve; Cross-Sectional Studies; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Middle Aged; Organophosphonates; Pilot Projects; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2009 |
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2009 |
Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrimidinones; Retrospective Studies; RNA, Viral; Stavudine; Tenofovir; Treatment Outcome; Young Adult | 2009 |
Modified directly observed therapy to improve HIV treatment outcomes: little impact with potent, once-daily therapy in unselected antiretroviral-naïve patients.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Medication Adherence; Organophosphonates; Pyrimidinones; Ritonavir; Self Administration; Stavudine; Tenofovir; Treatment Outcome | 2009 |
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Gastrointestinal Diseases; HIV Infections; HIV-1; Humans; Irritable Bowel Syndrome; Lopinavir; Male; Medication Adherence; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Pyrimidinones; Quality of Life; Ritonavir; Surveys and Questionnaires; Tenofovir; Young Adult | 2010 |
Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized t
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Organophosphonates; Pyrimidinones; Ritonavir; Tenofovir | 2010 |
Antiretroviral therapies in women after single-dose nevirapine exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Kaplan-Meier Estimate; Linear Models; Lopinavir; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Ritonavir; Statistics, Nonparametric; Tenofovir; Treatment Failure; Young Adult | 2010 |
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.
Topics: Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Carbamates; Confidence Intervals; Drug Administration Schedule; Drug Combinations; Dyslipidemias; Furans; HIV Infections; HIV-1; Humans; Insulin; Insulin Resistance; Lamivudine; Lipids; Lopinavir; Male; Organophosphates; Organophosphonates; Pyrimidinones; Ritonavir; Sulfonamides; Tenofovir | 2010 |
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genetic Association Studies; HIV Infections; HIV-1; Humans; Lopinavir; Male; Mutation; Organophosphonates; Polymorphism, Genetic; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Failure; Viral Load | 2011 |
Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Topics: Adenine; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2011 |
Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Central African Republic; DNA Fingerprinting; Drug Resistance, Viral; Female; Genetic Variation; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load; Young Adult; Zidovudine | 2012 |
Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Lopinavir; Malaria; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2012 |
Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
Topics: Adenine; Androstenes; Anti-HIV Agents; Atazanavir Sulfate; Atorvastatin; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Interactions; Emtricitabine; Ethinyl Estradiol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Least-Squares Analysis; Linear Models; Lopinavir; Male; Oligopeptides; Organophosphonates; Patient Safety; Phosphinic Acids; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tenofovir | 2012 |
Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Cognition Disorders; Depression; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2012 |
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Topics: Adenine; Adult; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Ritonavir; Tenofovir | 2012 |
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Immune Tolerance; Lopinavir; Male; Organophosphonates; Peptide Fragments; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2013 |
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Pilot Projects; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA Stability; RNA, Viral; Tenofovir; Viral Load | 2013 |
Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kidney; Kidney Function Tests; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Tenofovir; Viral Load | 2013 |
Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Kidney Diseases; Lopinavir; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2014 |
HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; Genitalia; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Risk Factors; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Virus Shedding | 2014 |
Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Body Composition; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tomography, X-Ray Computed; Young Adult | 2014 |
Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
Topics: Adenine; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Pressure; Body Mass Index; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Cholesterol, HDL; Cholesterol, LDL; Deoxycytidine; Emtricitabine; Endpoint Determination; Female; HIV Infections; HIV-1; Humans; Linear Models; Logistic Models; Lopinavir; Multivariate Analysis; Nevirapine; Organophosphonates; Prospective Studies; Risk Factors; Ritonavir; RNA, Viral; Tenofovir; Triglycerides | 2014 |
A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Gene Expression Regulation; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Organophosphonates; Ritonavir; Subcutaneous Fat; Tenofovir; Transcriptome | 2014 |
Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa.
Topics: Adenine; Adult; Africa; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Nevirapine; Organophosphonates; Ritonavir; Tenofovir; Treatment Outcome | 2014 |
First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2014 |
Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patients.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adipogenesis; Adiponectin; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; CCAAT-Enhancer-Binding Proteins; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Energy Metabolism; Female; Gene Expression; Glucose; Glucose Transporter Type 4; HIV-1; Humans; Inflammation; Lipid Metabolism; Lipoprotein Lipase; Lopinavir; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Subcutaneous Fat; Tenofovir | 2014 |
Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Biomarkers; Bone Remodeling; Bone Resorption; Collagen Type I; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Peptides; Ritonavir; Tenofovir; Young Adult | 2015 |
Week 120 efficacy of tenofovir, lamivudine and lopinavir/r-based second-line antiretroviral therapy in treatment-experienced HIV patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; China; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Ritonavir; Tenofovir | 2015 |
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Ritonavir; South Australia; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Proportional Hazards Models; Pyridines; Pyrones; Ritonavir; Sulfonamides; Tenofovir; Young Adult | 2016 |
Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Surveys and Questionnaires; Tenofovir; Treatment Outcome | 2016 |
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-lin
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; CD4 Lymphocyte Count; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; International Cooperation; Lamivudine; Lopinavir; Male; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2017 |
Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Post-Exposure Prophylaxis; Prospective Studies; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tablets; Tenofovir | 2017 |
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Developing Countries; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2019 |
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Logistic Models; Lopinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Risk; Ritonavir; Tenofovir; Ultrasonography, Prenatal; Young Adult; Zidovudine | 2019 |
Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.
Topics: Adenine; Anti-HIV Agents; Case-Control Studies; Chromatography, Liquid; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Lopinavir; Medication Adherence; Organophosphates; Polyphosphates; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Retrospective Studies; Ritonavir; Tenofovir | 2020 |
Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Bone Density; Breast Feeding; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Postpartum Period; Ritonavir; Tenofovir; Young Adult | 2021 |
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Child; Darunavir; Emtricitabine; Fumarates; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Ritonavir; Tenofovir | 2023 |
73 other study(ies) available for tenofovir and lopinavir
| Article | Year |
|---|---|
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amniotic Fluid; Anti-HIV Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Fetal Blood; Genitalia, Female; HIV-1; Humans; Hydrocortisone; Pregnancy; Pregnancy Complications, Infectious; RNA, Viral | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |
Upcoming compassionate use programs for two new antiretrovirals will begin this fall.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organophosphonates; Organophosphorus Compounds; Patient Selection; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir | 1999 |
Expanded access.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drugs, Investigational; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir | 1999 |
Antiretroviral news from ICAAC 2000.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Drug Resistance; HIV Infections; Humans; Lopinavir; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Ritonavir; Tenofovir | 2000 |
Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Diabetes Insipidus, Nephrogenic; Didanosine; Drug Therapy, Combination; Fanconi Syndrome; Humans; Lopinavir; Male; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Ritonavir; Tenofovir | 2003 |
French investigators warn of LPV/TDF/ddI interaction.
Topics: Adenine; CD4 Lymphocyte Count; Didanosine; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2003 |
[5 years' data are convincing. Lopinavir as primary therapy is effective and safe in the long term].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Long-Term Care; Lopinavir; Organophosphonates; Oxazines; Pyrimidinones; Ritonavir; Tenofovir; Viral Load | 2004 |
Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
Topics: Adenine; Adult; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Female; Gabon; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lopinavir; Microbial Sensitivity Tests; Mutation; Organophosphonates; Pyrimidinones; Tenofovir; Viral Load | 2005 |
Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Chemical Analysis; Creatinine; Fanconi Syndrome; Female; HIV Infections; Humans; Hypophosphatemia; Lopinavir; Male; Organophosphonates; Phosphates; Prospective Studies; Pyrimidinones; Reproducibility of Results; Tenofovir; Urea | 2005 |
Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.
Topics: Adenine; Anti-HIV Agents; Child; Diabetes Insipidus, Nephrogenic; Didanosine; Drug Therapy, Combination; Fanconi Syndrome; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Diseases; Lopinavir; Organophosphonates; Pregnancy; Pregnancy Complications; Pyrimidinones; Ritonavir; Tenofovir | 2006 |
Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Anti-HIV Agents; beta 2-Microglobulin; Biomarkers; Creatinine; Female; HIV Infections; HIV-1; Humans; Kidney Tubules; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrimidinones; Tenofovir; Thinness | 2006 |
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.
Topics: Adenine; Anti-HIV Agents; Cell Survival; Cells, Cultured; Didanosine; DNA, Mitochondrial; Drug Interactions; Electron Transport Complex IV; Humans; Kidney Tubules, Proximal; Lopinavir; Mitochondria; Organophosphonates; Pyrimidinones; Ritonavir; RNA; Tenofovir; Zidovudine | 2006 |
Progressive multifocal leukoencephalopathy: serial high-b-value diffusion-weighted MR imaging and apparent diffusion coefficient measurements to assess response to highly active antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brain; Diffusion; Diffusion Magnetic Resonance Imaging; HIV Protease Inhibitors; Humans; Leukoencephalopathy, Progressive Multifocal; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; Tenofovir; Zidovudine | 2007 |
Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Peptide Fragments; Pyrimidinones; Ritonavir; Tenofovir; Viral Load; Viremia | 2007 |
Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey.
Topics: Adenine; Anti-Retroviral Agents; CD4 Lymphocyte Count; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Mutation; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2007 |
HPV oral infection. Case report of an HIV-positive Nigerian sex worker.
Topics: Adenine; Adult; Alphapapillomavirus; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Italy; Lamivudine; Lopinavir; Mouth Mucosa; Nigeria; Organophosphonates; Papillomavirus Infections; Pyrimidinones; Ritonavir; Sex Work; Stomatitis; Tenofovir; Treatment Refusal; Zidovudine | 2007 |
Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Highly Active; Area Under Curve; Camptothecin; Drug Therapy, Combination; HIV Infections; Humans; Irinotecan; Lamivudine; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrimidinones; Ritonavir; Sarcoma, Kaposi; Tenofovir; White People | 2008 |
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Genitalia, Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2007 |
Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance.
Topics: Adenine; Creatinine; Drug Interactions; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Tubules; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; Sensitivity and Specificity; Tenofovir | 2008 |
96-week CASTLE data show similar efficacy results.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2008 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir | 2009 |
Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Body Fat Distribution; CD4 Lymphocyte Count; Deoxyguanosine; F2-Isoprostanes; Glutathione; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Male; Mitochondria; Organophosphonates; Pyrimidinones; Ritonavir; Stavudine; Tenofovir; Treatment Outcome; Viral Load | 2009 |
FDA approves three generics.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drugs, Generic; HIV Infections; Humans; Lamivudine; Lopinavir; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; United States; United States Food and Drug Administration | 2009 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Proportional Hazards Models; Prospective Studies; Pyridines; Pyrimidinones; Risk Factors; Switzerland; Tenofovir; Zidovudine | 2010 |
DAART for human immunodeficiency virus-infected patients: Studying subjects not at risk for nonadherence and use of untested interventions.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Patient Compliance; Pyrimidinones; Randomized Controlled Trials as Topic; RNA, Viral; Stavudine; Tenofovir; Treatment Outcome; Young Adult | 2010 |
Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Post-Exposure Prophylaxis; Practice Guidelines as Topic; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2010 |
[Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast].
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cote d'Ivoire; Cyclopropanes; Drug Therapy, Combination; Enterobacter aerogenes; Enterobacteriaceae Infections; Fanconi Syndrome; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Malaria; Male; Middle Aged; Organophosphonates; Pyelonephritis; Pyrimidinones; Ritonavir; Tenofovir | 2011 |
Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Markov Chains; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Tenofovir; United States | 2011 |
Antiretroviral therapy alone resulted in successful resolution of large idiopathic esophageal ulcers in a patient with acute retroviral syndrome.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Esophageal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; RNA, Viral; Syndrome; Tenofovir; Ulcer | 2011 |
Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-2; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Salvage Therapy; Tenofovir; Treatment Outcome; Viral Load | 2011 |
Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Epidemiologic Methods; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Mexico; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
Recent HIV-1 infection: to treat or not to treat, that is the question.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Ritonavir; Tenofovir; Viral Load | 2012 |
Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Hip Fractures; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Osteoporotic Fractures; Retrospective Studies; Risk; Risk Factors; Ritonavir; Spinal Fractures; Tenofovir; Time Factors; Treatment Outcome; Wrist Injuries; Young Adult | 2012 |
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Africa; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; Health Resources; Humans; India; Lopinavir; Male; Medication Adherence; Middle Aged; Mutation; Organophosphonates; Patient Selection; Pilot Projects; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Surveys and Questionnaires; Tenofovir; Thailand; Treatment Failure; Viral Load | 2012 |
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Time Factors | 2013 |
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; Glycosuria; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Proteinuria; Pyridines; Retrospective Studies; Ritonavir; Tenofovir | 2013 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Comorbidity; Cross-Sectional Studies; Cyclopropanes; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Echocardiography; Female; Furans; HIV Infections; Humans; Hypertension; Hypertrophy, Left Ventricular; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Ritonavir; Smoking; Spain; Sulfonamides; Tenofovir; Zidovudine | 2013 |
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Lamivudine; Lopinavir; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; Time Factors; United States | 2013 |
[Ophthalmological alterations at the initial diagnosis of HIV infection].
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Early Diagnosis; Emtricitabine; Eye Infections, Viral; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Organophosphonates; Retinal Diseases; Syndrome; Tenofovir; Treatment Outcome; Triazoles; Zidovudine | 2014 |
Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of anti-HIV drugs Lopinavir, Ritonavir, and Tenofovir in plasma.
Topics: Adenine; Animals; Anti-HIV Agents; Chromatography, Liquid; Lopinavir; Macaca nemestrina; Organophosphonates; Ritonavir; Tandem Mass Spectrometry; Tenofovir | 2014 |
Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood.
Topics: Adenine; Animals; Anti-HIV Agents; Blood Cells; Drug Carriers; Drug Combinations; Lopinavir; Lymph Nodes; Macaca nemestrina; Nanoparticles; Organophosphonates; Plasma; Ritonavir; Tenofovir | 2014 |
Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Emtricitabine; Female; France; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Failure; Viral Load | 2014 |
Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Carriers; Drug Combinations; HIV Infections; HIV Protease Inhibitors; HIV-1; Indinavir; Lipids; Lopinavir; Lymph Nodes; Macaca; Nanoparticles; Organophosphonates; Ritonavir; Tenofovir; Viral Load; Virus Latency | 2015 |
Fibroblast growth factor 23: associations with antiretroviral therapy in patients co-infected with HIV and hepatitis C.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Bayes Theorem; Benzoxazines; Canada; Coinfection; Cyclopropanes; Dideoxynucleosides; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Hepatitis C; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Prospective Studies; Risk Factors; Tenofovir | 2016 |
Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; China; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Mutation; Prospective Studies; Ritonavir; RNA, Viral; Rural Population; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Seropositivity; Humans; Incidence; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Post-Exposure Prophylaxis; Quebec; Ritonavir; Tenofovir; Young Adult; Zidovudine | 2015 |
Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Comorbidity; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2016 |
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Proportional Hazards Models; Raltegravir Potassium; Retrospective Studies; Risk; Tenofovir | 2016 |
A Direct Comparison of the Effects of the Antiretroviral Drugs Stavudine, Tenofovir and the Combination Lopinavir/Ritonavir on Bone Metabolism in a Rat Model.
Topics: Animals; Anti-HIV Agents; Bone and Bones; Bone Remodeling; Drug Combinations; Lopinavir; Male; Rats; Rats, Wistar; Ritonavir; Stavudine; Tenofovir | 2017 |
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Clinical Decision-Making; Computational Biology; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Monitoring, Physiologic; Nevirapine; pol Gene Products, Human Immunodeficiency Virus; Stavudine; Tanzania; Tenofovir; Treatment Failure; Viral Load | 2017 |
Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV-1; Humans; Lopinavir; Mutation; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Tenofovir | 2017 |
Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.
Topics: Anti-HIV Agents; Cross-Sectional Studies; Female; Genotype; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Pharmacogenetics; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Thailand | 2017 |
Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation.
Topics: Animals; Anti-HIV Agents; Anti-Retroviral Agents; Delayed-Action Preparations; Drug Combinations; Lopinavir; Macaca nemestrina; Male; Models, Biological; Nanoparticles; Ritonavir; Tenofovir | 2018 |
Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.
Topics: Animals; Anti-HIV Agents; Drug Carriers; Drug Delivery Systems; Drug Therapy, Combination; HIV Infections; Injections, Subcutaneous; Lamivudine; Leukocytes, Mononuclear; Lopinavir; Lymph Nodes; Macaca nemestrina; Male; Nanoparticles; Ritonavir; Tenofovir | 2018 |
Tenofovir disoproxil fumarate co-administered with lopinavir/ritonavir is strongly associated with tubular damage and chronic kidney disease.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Kidney Tubules; Lopinavir; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors; Ritonavir; Tenofovir; Vietnam | 2018 |
Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Disease Transmission, Infectious; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infant, Low Birth Weight; Infant, Newborn; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Risk; Ritonavir; Tenofovir; Zidovudine | 2018 |
Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates.
Topics: Alkynes; Animals; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Blood Cells; Cyclopropanes; Delayed-Action Preparations; Drug Combinations; Injections, Subcutaneous; Lopinavir; Macaca; Male; Nanoparticles; Plasma; Suspensions; Tenofovir | 2018 |
A three-in-one, long-acting, nanosuspension reformulation of off-patent antiretrovirals for low-income and middle-income countries.
Topics: Alkynes; Animals; Benzoxazines; Cyclopropanes; HIV Infections; Lopinavir; Primates; Tenofovir | 2018 |
Multidrug nanosuspensions: future perspectives on drug delivery system for HIV combination antiretroviral therapy.
Topics: Alkynes; Animals; Benzoxazines; Cyclopropanes; Drug Delivery Systems; HIV; HIV Infections; Lopinavir; Primates; Tenofovir | 2018 |
Descriptive analysis of World Health Organization-recommended second-line antiretroviral treatment: A retrospective cohort data analysis.
Topics: Adult; Age Factors; CD4 Lymphocyte Count; Databases, Factual; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Lost to Follow-Up; Male; Medication Adherence; Middle Aged; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Sex Factors; Tenofovir; Treatment Failure; Viral Load; World Health Organization; Zidovudine | 2019 |
Advance of promising targets and agents against COVID-19 in China.
Topics: Adenine; Adenosine Monophosphate; Alanine; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Cobicistat; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Dibenzothiepins; Drug Combinations; Drug Discovery; Drug Therapy, Combination; Emtricitabine; Humans; Hydroxychloroquine; Indoles; Lopinavir; Medicine, Chinese Traditional; Morpholines; Oseltamivir; Oxazines; Pandemics; Pneumonia, Viral; Pyrazines; Pyridines; Pyridones; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tenofovir; Thiepins; Triazines; Viral Nonstructural Proteins | 2020 |
COVID-19 research: an opinion piece.
Topics: Anti-Retroviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Research; Ritonavir; SARS-CoV-2; Tenofovir; Time Factors | 2020 |
Cases of coronavirus disease-2019 in HIV-infected transgender women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Oxazines; Pandemics; Piperazines; Pneumonia, Viral; Pyridones; Ritonavir; SARS-CoV-2; Tenofovir; Transgender Persons | 2020 |
FGF21 and its Relationship with Inflammatory and Metabolic Parameters in HIV Patients after Antiretroviral Treatment.
Topics: Adult; Anti-Retroviral Agents; Atherosclerosis; Female; Fibroblast Growth Factors; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Inflammation; Inflammation Mediators; Lipid Metabolism; Lopinavir; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Risk Factors; Ritonavir; Tenofovir; Young Adult | 2020 |
Controlled Solvent Removal from Antiviral Drugs and Excipients in Solution Enables the Formation of Novel Combination Multi-Drug-Motifs in Pharmaceutical Powders Composed of Lopinavir, Ritonavir and Tenofovir.
Topics: Antiviral Agents; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Drug Combinations; Excipients; Lopinavir; Microscopy, Electron, Scanning; Particle Size; Powders; Ritonavir; Solvents; Tenofovir; X-Ray Diffraction | 2020 |
Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture.
Topics: Animals; HIV Infections; Lopinavir; Lymphatic System; Ritonavir; Tenofovir | 2022 |
Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination Nanoparticles.
Topics: Drug Combinations; HIV Infections; Humans; Lopinavir; Lymphatic System; Models, Biological; Nanoparticles; Tenofovir | 2022 |
Osteonecrosis of the humeral head in a human immunodeficiency virus-infected patient under tenofovir disoproxil fumarate-emtricitabine-lopinavir/ritonavir for 10 years: a case report.
Topics: Emtricitabine; Female; HIV; HIV Infections; Humans; Humeral Head; Lopinavir; Middle Aged; Osteonecrosis; Ritonavir; Tenofovir | 2021 |